T1	intervention 117 128	alendronate
T2	intervention 133 148	zoledronic acid
T3	No-of-participants 682 686	6459
T4	average-age 698 712	55 to 81 years
T5	control 731 738	placebo
T6	duration 763 772	3.8 years
T7	No-of-participants 904 908	7765
T8	location 1109 1171	Asia and the Pacific, Europe, North America, and South America
T9	outcome-Measure 1464 1532	compared events in the active vs placebo group using a log-rank test
T10	outcome 1625 1647	incident breast cancer
T11	outcome 1760 1781	rate of breast cancer
T12	control-value 1790 1794	1.5%
T13	control-value 1800 1802	46
T14	intervention-value 1829 1833	1.8%
T15	intervention-value 1838 1841	â€‰57
